![John Tsai](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
John Tsai
Direttore Tecnico/Scientifico/R&S presso
DAIICHI SANKYO COMPANY, LIMITED
Profilo
Attualmente, John Tsai è Chief Medical Officer presso Novartis AG. Nella sua carriera passata il Dr. Tsai è stato Chief Medical Officer & SVP-Global Medical presso Amgen, Inc. e Head-Clinical Development presso Bristol Myers Squibb Co. Ha ricevuto un dottorato dalla University of Louisville School of Medicine e una laurea presso la Washington University di St.
Posizioni attive di John Tsai
| Società | Posizione | Inizio |
|---|---|---|
| SYNCONA LIMITED | Corporate Officer/Principal | 01/01/2023 |
| DAIICHI SANKYO COMPANY, LIMITED | Direttore Tecnico/Scientifico/R&S | 01/04/2026 |
Forcefield Therapeutics Ltd.
 Forcefield Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics to retain heart function via protection of cardiomyocytes | Amministratore Delegato | 27/09/2023 |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage gene therapy company that develops therapeutics for neurological disorders | Presidente | 16/10/2023 |
Purespring Therapeutics Ltd.
 Purespring Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics for the treatment of kidney diseases | Presidente | - |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which developing gene therapies for bleeding and other debilitating disorders | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di John Tsai
| Società | Posizione | Fine |
|---|---|---|
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements. | Investitore di Private Equity | 01/02/2026 |
| BLUEPRINT MEDICINES CORPORATION | Direttore/Membro del Consiglio | 17/07/2025 |
| NOVARTIS AG | Direttore Tecnico/Scientifico/R&S | 15/05/2022 |
| ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formazione di John Tsai
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
86
Relazioni di 1° grado
14
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 14 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Washington University in St. Louis
 Washington University in St. Louis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Syncona Ltd.
 Syncona Ltd. Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Daiichi Sankyo Co., Ltd.
 Daiichi Sankyo Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in the manufacture and sale of pharmaceutical products | Health Technology |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts research related to biotechnology and medicine | Commercial Services |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements. | Finance |
University of Louisville School of Medicine
 University of Louisville School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which developing gene therapies for bleeding and other debilitating disorders | Health Technology |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage gene therapy company that develops therapeutics for neurological disorders | Health Technology |
Purespring Therapeutics Ltd.
Purespring Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics for the treatment of kidney diseases | Health Technology |
Forcefield Therapeutics Ltd.
Forcefield Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics to retain heart function via protection of cardiomyocytes | Health Technology |
